Results 201 to 210 of about 16,658,609 (280)
Why CAR T cell therapy fails in renal cell carcinoma. [PDF]
Zhang HJ, Han LZ, Zhang X, Ge YL.
europepmc +1 more source
AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley +1 more source
Distinct roles of STAT3 and STAT5 in CAR T cell therapy. [PDF]
Kagoya Y.
europepmc +1 more source
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali +8 more
wiley +1 more source
IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia. [PDF]
Hocine HR +16 more
europepmc +1 more source
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas +4 more
wiley +1 more source
CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers. [PDF]
Liu L +6 more
europepmc +1 more source
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme +49 more
wiley +1 more source
Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia. [PDF]
Wang Y, Yu T, Wang M, Yu L.
europepmc +1 more source
Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy. [PDF]
Bhoj VG +36 more
europepmc +1 more source

